Abstract:The aggregation of soluble amyloid‐beta (Aβ) peptide into oligomers/fibrils is one of the key pathological features in Alzheimer's disease (AD). The Aβ aggregates are considered to play a pivotal role in the pathogenesis of AD. Therefore, inhibiting Aβ aggregation and destabilizing preformed Aβ fibrils would be an attractive therapeutic target for prevention and treatment of AD. S14G‐humanin (HNG), a synthetic derivative of Humanin (HN), has been shown to be a strong neuroprotective agent against various AD‐related insults. Recent studies have shown that HNG can significantly improve cognitive deficits and reduce insoluble Aβ levels as well as amyloid plaque burden without affecting amyloid precursor protein processing and Aβ production in transgenic AD models. However, the potential mechanisms by which HNG reduces Aβ‐related pathology in vivo remain obscure. In the present study, we found that HNG could significantly inhibit monomeric Aβ1–42 aggregation into fibrils and destabilize preformed Aβ1–42 fibrils in a concentration‐dependent manner by Thioflavin T fluorescence assay. In transmission electron microscope study, we observed that HNG was effective in inhibiting Aβ1–42 fibril formation and disrupting preformed Aβ1–42 fibrils, exhibiting various types of amorphous aggregates without identifiable Aβ fibrils. Furthermore, HNG‐treated monomeric or fibrillar Aβ1–42 was found to significantly reduce Aβ1–42‐mediated cytotoxic effects on PC12 cells in a dose‐dependent manner by MTT assay. Collectively, our results demonstrate for the first time that HNG not only inhibits Aβ1–42 fibril formation but also disaggregates preformed Aβ1–42 fibrils, which provides the novel evidence that HNG may have anti‐Aβ aggregation and fibrillogenesis, and fibril‐destabilizing properties. Together with previous studies, we concluded that HNG may have promising therapeutic potential as a multitarget agent for the prevention and/or treatment of AD. Copyright © 2013 European Peptide Society and John Wiley & Sons, Ltd.

S14G-humanin inhibits Aβ1-42 fibril formation, disaggregates preformed fibrils, and protects against Aβ-induced cytotoxicity in vitro.

Retracted: S14G‐humanin Inhibits Aβ1–42 Fibril Formation, Disaggregates Preformed Fibrils, and Protects Against Aβ‐induced Cytotoxicity in Vitro

Protective Effect of S14G-humanin Against Beta-Amyloid Induced LTP Inhibition in Mouse Hippocampal Slices.

Humanin peptides block calcium influx of rat hippocampal neurons by altering fibrogenesis of Aβ1–40

RETRACTED: S14G-Humanin Ameliorates Aβ25-35-induced Behavioral Deficits by Reducing Neuroinflammatory Responses and Apoptosis in Mice

S14G-Humanin Improves Cognitive Deficits and Reduces Amyloid Pathology in the Middle-Aged APPswe/PS1dE9 Mice

Protective effects of [Gly14]-Humanin on β-amyloid-induced PC12 cell death by preventing mitochondrial dysfunction

Effect of humanin and [Gly14]-humanin on expression of hippocampal glial fibrillary acidic protein in mice with Alzheimer disease

Humanin Analogue, HNG, Inhibits Platelet Activation and Thrombus Formation by Stabilizing Platelet Microtubules

C3N Nanodots Inhibits Aβ Peptides Aggregation Pathogenic Path in Alzheimer's Disease.

Ginnalin A Inhibits Aggregation, Reverses Fibrillogenesis, and Alleviates Cytotoxicity of Amyloid (1-42)

Inhibiting Β-Amyloid-associated Alzheimer’s Pathogenesis in Vitro and in Vivo by a Multifunctional Dimeric Bis(12)-hupyridone Derived from Its Natural Analogue

Α-mangostin, a polyphenolic xanthone derivative from mangosteen, attenuates β-amyloid oligomers-induced neurotoxicity by inhibiting amyloid aggregation.

Plasminogen decreases Aβ42 and Tau deposition, and shows multi-beneficial effects on Alzheimer's disease in mice and humans

[Gly14]-Humanin Reduces Histopathology and Improves Functional Outcome after Traumatic Brain Injury in Mice.

Involvement of Intracellular and Mitochondrial Aβ in the Ameliorative Effects of Huperzine A Against Oligomeric Aβ42-Induced Injury in Primary Rat Neurons

Natural flavonoid hesperetin blocks amyloid β-protein fibrillogenesis, depolymerizes preformed fibrils and alleviates cytotoxicity caused by amyloids

Biological effects and mechanism of β-amyloid aggregation inhibition by penetrable recombinant human HspB5-ACD structural domain protein

Human Anti-Beta-Amyloid Antibodies Block Beta-Amyloid Fibril Formation and Prevent Beta-Amyloid-Induced Neurotoxicity

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

The nickel-chelator dimethylglyoxime inhibits human amyloid beta peptide in vitro aggregation